Colchicine in Coronary Artery Disease: Comparative Review of CLEAR SYNERGY, LoDoCo2 and COLCOT.
Level 5 - mechanism / opinion, no new human data
Narrative comparative review of three randomized controlled trials without systematic review or meta-analysis
PubMed 41528549 · doi:10.1007/s11883-025-01382-z
What was done
This review examined methodological and clinical differences across three large randomized controlled trials evaluating colchicine for secondary prevention in coronary artery disease: COLCOT, LoDoCo2, and CLEAR SYNERGY. The authors compared study designs, patient populations, timing of treatment initiation, dosing regimens, geographic factors, trial timing, and inflammatory response markers.
What was found
COLCOT (in patients with recent myocardial infarction) and LoDoCo2 (in patients with chronic coronary syndrome) showed relative risk reductions in major adverse cardiovascular events of 23% and 31%, respectively. In contrast, the CLEAR SYNERGY trial (in patients with recent myocardial infarction) yielded neutral results. The comparative review noted that observed differences between trials do not provide definitive answers for the divergent outcomes.
Why it matters
Colchicine targets NLRP3 inflammasome activity to reduce downstream inflammatory cytokines, but conflicting large-scale trial results complicate its clinical adoption for secondary cardiovascular prevention. Identifying potential sources of trial divergence helps direct future subgroup and landmark analyses.
Limits
This is a narrative comparative review synthesizing three previously published trials without formal systematic review methodology or pooled quantitative meta-analysis. The abstract provides no new primary human data or definitive explanations for the neutral CLEAR SYNERGY results.
Cited by
- supports A specific dose of colchicine significantly reduces cardiovascular risk in patients with a prior heart attack, particularly those with diabetes, and is FDA approved for this indication.